“…In addition, reducing YB-1 levels in tumour xenograft models of breast, brain, lung and pharyngeal cancers inhibited cell proliferation [ 4 , 8 , 9 ]. Furthermore, YB-1 has also been implicated in regulating the proliferation of breast cancer, large B-cell lymphoma, lung adenocarcinoma, neuroblastoma, hepatocellular carcinoma, glioma, renal cell carcinoma and melanoma in vitro [ 4 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ]. YB-1 has been implicated in regulating many genes involved in proliferation [ 10 , 11 , 12 , 13 , 14 , 15 ] and survival, reviewed in [ 1 , 17 ], including the 70-gene breast cancer “signature” [ 18 ] and the E2F family gene cluster [ 4 ].…”